Chronic oral administration of ginseng extract results in behavioral change but has no effects in mice models of affective and anxiety disorders

Phytotherapy Research

Volumn 21, Issue 1, 2007, Pages 62-66

  Einat, Haim ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Animal models; Anxiety; Bipolar disorder; Depression; Natural products; Neuroprotection

Indexed keywords

AMPHETAMINE; ANTIDEPRESSANT AGENT; GINSENG EXTRACT; GINSENOSIDE; MOOD STABILIZER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DEPRESSION; DRUG ACTIVITY; DRUG EFFECT; HYPERACTIVITY; LOCOMOTION; MALE; MANIA; MOOD DISORDER; MOUSE; NEUROPROTECTION; NONHUMAN; SWIMMING; TRANQUILIZING ACTIVITY;

ADMINISTRATION, ORAL; AMPHETAMINES; ANIMALS; ANTIDEPRESSIVE AGENTS; ANXIETY; BEHAVIOR, ANIMAL; MALE; MICE; MICE, INBRED C57BL; PANAX; PHYTOTHERAPY; PLANT EXTRACTS;

ANIMALIA; MUS; PANAX GINSENG;

EID: 33846604092     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2024     Document Type: Article

References (37)

1. Bai F, Li X, Clay M, Lindstrom T, Skolnick P. 2001. Intra- and interstrain differences in models of behavioral despair. Pharmacol Biochem Behav 70: 187-192.
2. Benjamin J, Agam G, Levine J, Bersudsky Y, Kofman O, Belmaker RH. 1995. Inositol treatment in psychiatry. Psychopharmacol Bull 31: 167-175.
3. Bertoglio LJ, Carobrez AP. 2002. Behavioral profile of rats submitted to session 1-session 2 in the elevated plus-maze during diurnal/nocturnal phases and under different illumination conditions. Behav Brain Res 132: 135-143.
4. Brunello N. 2004. Mood stabilizers: protecting the mood protecting the brain. J Affect Disord 79(Suppl 1): S15-S20.
5. Brunton LL, Lazo JS, Parker KL (eds). 2005. Goodman & Gilman's The Pharmacological Basis of Therapeutics, Mc Graw Hill: NYC.
6. Carr MN, Bekku N, Yoshimura H. 2006. Identification of anxiolytic ingredients in ginseng root using the elevated plus-maze test in mice. Eur J Pharmacol 531: 160-165.
7. Cha HY, Park JH, Hong JT et al. 2005. Anxiolytic-like effects of ginsenosides on the elevated plus-maze model in mice. Biol Pharm Bull 28: 1621-1625.
8. Coyle JT, Duman RS. 2003. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 38: 157-160.
9. Crawley JN. 1999. Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res 835: 18-26.
10. Duman RS. 2002. Pathophysiology of depression: the concept of synaptic plasticity. Eur Psychiatry 17(Suppl 3): 306-310.
11. Einat H, Clenet F, Shaldubina A, Belmaker RH, Bourin M. 2001. The antidepressant activity of inositol in the forced swim test involves 5-HT(2) receptors. Behav Brain Res 118: 77-83.
12. Einat H, Karbovski H, Korik J, Tsalah D, Belmaker RH. 1999. Inositol reduces depressive-like behaviors in two different animal models of depression. Psychopharmacology (Berl) 144: 158-162.
13. Einat H, Manji HK, Belmaker RH. 2003a. New approaches to modeling bipolar disorder. Psychopharmacol Bull 37: 47-63.
14. Einat H, Yuan P, Dogra S, Manji HK. 2003b. Does the PKC signaling pathway play a role in the pathophysiology and treatment of bipolar disorder? Biol Psychiatry 53(Suppl 8): S399.
15. Einat H, Yuan P, Gould TD et al. 2003c. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 23: 7311-7316.
16. Einat H, Yuan P, Manji HK. 2005. Increased anxiety-like behaviors and mitochondrial dysfunction in mice with targeted mutation of the Bcl-2 gene: Further support for the involvement of mitochondrial function in anxiety disorders. Behav Brain Res 165: 172-180.
17. Fugh-Berman A, Cott JM. 1999. Dietary supplements and natural products as psychotherapeutic agents. Psychosom Med 61: 712-728.
18. Gould TD, Einat H, Bhat R, Manji HK. 2004. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 7: 387-390.
19. Ji YC, Kim YB, Park SW et al. 2005. Neuroprotective effect of ginseng total saponins in experimental traumatic brain injury. J Korean Med Sci 20: 291-296.
20. Kim DH, Moon YS, Jung JS et al. 2003. Effects of ginseng saponin administered intraperitoneally on the hypothalamo-pituitary-adrenal axis in mice. Neurosci Lett 343: 62-66.
21. Lee EH, Cho SY, Kim SJ et al. 2003. Ginsenoside F1 protects human HaCaT keratinocytes from ultraviolet-B-induced apoptosis by maintaining constant levels of Bcl-2. J Invest Dermatol 121: 607-613.
22. Lee JY, Kim JW, Cho SD et al. 2004. Protective effect of ginseng extract against apoptotic cell death induced by 2,2′,5,5′- tetrachlorobiphenyl in neuronal SK-N-MC cells. Life Sci 75: 1621-1634.
23. Manji HK, Duman RS. 2001. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull 35: 5-49.
24. Manji HK, Quiroz JA, Sporn J et al. 2003. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 53: 707-742.
25. Nestler EJ, Gould E, Manji H et al. 2002. Preclinical models: status of basic research in depression. Biol Psychiatry 52: 503-528.
26. Park EK, Choo MK, Oh JK, Ryu JH, Kim DH. 2004. Ginsenoside Rh2 reduces ischemic brain injury in rats. Biol Pharm Bull 27: 433-436.
27. Park JH, Cha HY, Seo JJ, Hong JT, Han K, Oh KW. 2005. Anxiolytic-like effects of ginseng in the elevated plus-maze model: comparison of red ginseng and sun ginseng. Prog Neuropsychopharmacol Biol Psychiatry 29: 895-900.
28. Park MK, Park JH, Han SB, Shin YG, Park IH. 1996. High performance liquid chromatographic analysis of ginseng saponins using evaporative light scattering detection. J Chromatogr A 736: 77-81.
29. Porsolt RD, Bertin A, Jalfre M. 1977. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229: 327-336.
30. Radad K, Gille G, Moldzio R, Saito H, Ishige K, Rausch WD. 2004a. Ginsenosides Rb1 and Rg1 effects on survival and neurite growth of MPP+-affected mesencephalic dopaminergic cells. J Neural Transm 111: 37-45.
31. Radad K, Gille G, Moldzio R, Saito H, Rausch WD. 2004b. Ginsenosides Rb1 and Rg1 effects on mesencephalic dopaminergic cells stressed with glutamate. Brain Res 1021: 41-53.
32. Rudakewich M, Ba F, Benishin CG. 2001. Neurotrophic and neuroprotective actions of ginsenosides Rb(1) and Rg(1). Planta Med 67: 533-537.
33. Sadock J, Kaplan H. 2002. Synopsis of Psychiatry. Philadelphia, PA: Lippincott & Williams.
34. Van Kampen J, Robertson H, Hagg T, Drobitch R. 2003. Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease. Exp Neurol 184: 521-529.
35. Willner P. 1995. Animal models of depression: validity and applications. Depression and Mania: from Neurobiology to Treatment, Gessa GL, Fratta W, Pani L, Serra G (eds). Raven Press: New York, 49: 19-42.
36. Wu CF, Liu YL, Song M et al. 2003. Protective effects of pseudoginsenoside-F11 on methamphetamine-induced neurotoxicity in mice. Pharmacol Biochem Behav 76: 103-109.
37. Yuan PX, Zhou R, Farzad N et al. 2005. Enhancing resilience to stress: the role of signaling cascades. In Handbook on Stress and the Brain, Steckler N, Kalin JM, Reul HM (eds). Elsevier. 1: 5.7.